An exploratory study on the treatment of stage III colon cancer with special prescription of removing dampness and removing dampness after postoperative chemotherapy

Phase 1

Recruiting

Conditions: Colon cancer

Registration Number: ITMCTR2000003424

Lead Sponsor: Oncology Department, Guangdong Provincial Hospital of Chinese Medicine

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

1. Patients with colon cancer confirmed by histopathology or cytopathology;
2. Patients who have undergone radical surgery and whose postoperative pathological stage is stage III and T4 or N2 (according to NCCN clinical practice guideline colorectal cancer (2018 V4) standard);
3. Adjuvant chemotherapy has been completed (for example, 4-8 XELOX, 6-12 FOLFOX, or fluorouracil single drug chemotherapy has been completed, and no adjuvant chemotherapy will be accepted in the near future);
4. The patients without recurrence and metastasis were reexamined in the past 1 month;
5. Patients whose last chemotherapy time was less than 3 months;
6. Patients with PS score (ECoG) <= 2;
7. Patients aged 18-75 years;
8. Patients with normal liver and kidney function;
Normal renal function: serum creatinine <= 1.5mg/dl (133 µ mol / L) and creatinine clearance >= 60ml / min;
Normal liver function: total serum bilirubin level <= 1.5 times of upper limit of normal value (ULN), serum AST and ALT 2.5 times of ULN;
9. The patients who sign the informed consent and are willing to receive the treatment of this program, can insist on taking medicine and have good compliance.

Exclusion Criteria

1. Patients who are unable to complete the baseline assessment form;
2. Patients with ileus or incomplete ileus;
3. Patients with other serious diseases, including uncontrolled active infection, severe electrolyte disorder, and obvious bleeding tendency;
4. Pregnant and lactating women;
5. Patients with autoimmune diseases and blood system diseases, or long-term use of hormone or immunosuppressant;
6. Patients with other uncontrolled tumors;
7. Patients who have received new adjuvant or adjuvant radiotherapy, or intend to receive radiotherapy;
8. Patients with serious brain disease or mental disease that affect the ability of self-report;
9. Have a history of organ transplantation (including bone marrow autotransplantation and peripheral stem cell transplantation);
10. Patients without legal capacity, and those who are affected by medical or ethical reasons.